for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

NanoViricides Inc

NNVC.A

Latest Trade

2.16USD

Change

-0.04(-1.82%)

Volume

7,296

Today's Range

2.13

 - 

2.22

52 Week Range

2.00

 - 

8.70

As of on the Nyse American LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
2.20
Open
2.20
Volume
7,296
3M AVG Volume
3.31
Today's High
2.22
Today's Low
2.13
52 Week High
8.70
52 Week Low
2.00
Shares Out (MIL)
11.53
Market Cap (MIL)
26.16
Forward P/E
-2.52
Dividend (Yield %)
--

Latest Developments

More

Nanoviricides Says Data Shows Pan-Coronavirus Nanopviricide Drug Candidate NV-Cov-2-R Minimizes Loss Of Remdesivir To Bodily Metabolism

Altium Capital Management LP Reports 7.2% Passive Stake In Nanoviricides

Nanoviricides Inc Files For Mixed Shelf Of Up To $150.0 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About NanoViricides Inc

NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is engaged in discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. The nanomedicines technology also enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company is developing antiviral drug candidate, NV-CoV-2 drug for the treatment of COVID-19 infected sick persons. Its other clinical drug candidate NV-HHV-101 a skin cream for the treatment of shingles rash.

Industry

Biotechnology & Drugs

Contact Info

1 Controls Drive

SHELTON, CT

06484

United States

+1.203.9376137

http://www.nanoviricides.com/

Executive Leadership

Anil Diwan

Chairman of the Board, President

Meeta Vyas

Chief Financial Officer

Stanley Glick

Independent Director

Makarand Jawadekar

Independent Director

Theodore Rokita

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
EPS (USD)

2022(E)

-0.900
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
0.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.08
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-31.30
Return on Equity (TTM)
-29.90

Latest News

Latest News

BRIEF-Nanoviricides Files For Offering For Sale, Directly To Selected Investors, 1.4 Mln Shares Of Common Stock At $7.30 Per Share

* NANOVIRICIDES INC FILES FOR OFFERING FOR SALE, DIRECTLY TO SELECTED INVESTORS, 1.4 MILLION SHARES OF COMMON STOCK AT $7.30 PER SHARE Source text: [https://bit.ly/2Tszz8T] Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Nanoviricides Inc Files For Mixed Shelf Of Up To $150.0 Million

* NANOVIRICIDES INC FILES FOR MIXED SHELF OF UP TO $150.0 MILLION - SEC FILING Source text: (https://bit.ly/33KZ2yk) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up